to detect small clinically significant tumors in areas that might go undetected on a standardized, random biopsy; on the other hand, clinically insignificant tumors are usually not seen on mpMRI. A recent meta--analysis has shown pooled sensitivities and specificities of 82% for prostate cancer detection in articles that accurately used the PI-RADS criteria (10) .
The digital images obtained on mpMRI can be used to improve ultrasound (US) guided biopsy procedures by using MRI-US fusion techniques, whether cognitive (when the radiologist or urologist visually defines the region of the suspected lesion on mpMR images and directs additional fragments to this region) or real-time (when the digital mpMR images are uploaded in the US equipment and allow real-time visualization of the concordant MR and US images during the biopsy). Many recent articles have demonstrated that, in comparison to random biopsy, fusion biopsy techniques improve in up to 30% the detection of clinically significant PCa (reducing disease morbidity and mortality), while decreasing the detection of insignificant disease (reducing overtreatment) (11, 12) .
By performing mpMRI prior to biopsy, a paradigm-shift is evolving, since lesions highly suspicious for clinically significant tumors are been locally staged by mpMRI before histological confirmation of the disease. This may sound unorthodox, given the historical algorithm of prostate cancer detection and staging, but is the usual workflow in many other tumors (such as kidney cancer), and might increases the capability of the radiologist to locally stage the disease in prostates without biopsy-related artifacts (Figure-1) .
Although mpMRI has been currently used for PCa detection in many centers, the definitive incor- poration of mpMRI in the screening algorithm of PCa in the general male population is still restricted by relevant issues: the exam is costly and time-consuming, the availability of 3-Tesla scanners is limited, and the need of contrast-injection for the perfusion part of the protocol carries the (small) risk of allergic reactions and other rare side-effects. Therefore, many center are investing on faster, cheaper, non-invasive and harmless MR protocols for PCa screening, generically called bi-parametric MRI (since it includes only T2 and diffusion-weighted sequences), which can perform on more widely available 1.5 Tesla scanners without an endorectal coil. Two recent articles demonstrated a good accuracy of bi-parametric MRI, associated with serum-PSA levels, for the detection of PCa in correlation to biopsy (13, 14) .
In conclusion, mpMRI has already been accepted as a valuable method for local staging in patients with intermediate to high-risk PCa. However, given the growing applicability of mpMRI for the screening of clinically significant tumors (and supported by some urologists' perspectives on prostate cancer imaging (15)), I would humbly suggest a rephrasing of the proposed theme of this article: in the near future, all men with suspicion for prostate cancer should undergo MRI.
